Status:
COMPLETED
The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and...
Eligibility Criteria
Inclusion
- Main
- Diagnosis of persistent chronic bronchial asthma
- Baseline lung function within specified parameters
- No change in asthma treatment during the last 4 weeks prior to start of baseline period
- Stable clinical state
- Except for asthma, in good health
- Non-smokers or ex-smokers
- Main
Exclusion
- Poorly controlled asthma
- Diagnosis of chronic pulmonary disease and/or other relevant lung diseases
- Patients using continuously (more than 3 days per week) \> 8 puffs/day rescue medication
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
June 1 2005
Estimated Enrollment :
822 Patients enrolled
Trial Details
Trial ID
NCT00076076
Start Date
December 1 2003
End Date
June 1 2005
Last Update
December 2 2016
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
ALTANA Pharma
Cities in Alabama, Alabama, United States
2
ALTANA Pharma
Cities in Arizona, Arizona, United States
3
ALTANA Pharma
Cities in Arkansas, Arkansas, United States
4
ALTANA Pharma
Cities in California, California, United States